NASDAQ: KYTX

Kyverna Therapeutics, Inc.

Healthcare | Biotechnology

No licensed closing price on file for KYTX. This page shows the company’s SEC filings and filed figures, without a price or any ratio that depends on one.

Kyverna Therapeutics, Inc. (NASDAQ: KYTX) is a biotechnology company. Figures from SEC EDGAR; updated 2026-10-20 08:00 UTC.

Key facts

Charts

Charts are in the appInteractive charts for KYTX are available in Oxford Ledge.
Open KYTX in Oxford Ledge →

SEC Filings

SEC EDGAR ↗

8-KEntry into material agreement; Financial statements and exhibits2026-07-09↗
8-KShareholder vote results; Financial statements and exhibits2026-06-02↗
8-KDeparture/election of directors or officers; Other material event; Financial statements and exhibits2026-05-18↗
10-QQuarterly financial report (unaudited)2026-05-12↗
8-KResults of operations / financial condition; Financial statements and exhibits2026-05-12↗

Recent Insider Activity

Source: SEC EDGAR · Filed 2026-05-29

Most recent filed transactions — May 2026:

2026-05-29DirectorAward5,093—
2026-05-29DirectorStock Option (right to buy)Award20,582—
2026-05-29DirectorAward5,093—

Top Institutional Holders (latest 13F)

Source: SEC EDGAR · As of 2026-Q2

GordonMD Global Investments LP4,244,818$37.82M0.0%
GILEAD SCIENCES, INC.4,126,119$36.76M0.0%
BlackRock, Inc.3,134,807$27.93M+257.4%

View QoQ ownership changes →Full institutional ownership →

Recent 8-K Events (parsed from SEC filings)All events →

Source: SEC EDGAR 8-K filings · Interpretation: Oxford Ledge parser · Confidence-filtered ≥ 0.50

2026-05-18Exec ChangeDeparture of directors or certain officers; election of directors; appointment of certain officers; compensatory arrangements of certain officersEstimatedSEC 8-K →
2026-02-24Exec ChangeDeparture of directors or certain officers; election of directors; appointment of certain officers; compensatory arrangements of certain officersEstimatedSEC 8-K →
2025-06-30Exec ChangeDeparture of directors or certain officers; election of directors; appointment of certain officers; compensatory arrangements of certain officersEstimatedSEC 8-K →

Company news

View all →

Kyverna Therapeutics, Inc. (KYTX) Discusses Positive Topline Data and Longer-Term Follow-Up for SPS and GMG Trials Transcript
seekingalpha.com2026-09-24POS
Kyverna Therapeutics, Inc. (KYTX) Discusses Positive Topline Data and Longer-Term Follow-Up for SPS and GMG Trials Transcript
Seeking Alpha Feed2026-09-24POS
Kyverna Therapeutics, Inc. (KYTX) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
seekingalpha.com2026-09-14
Kyverna Therapeutics, Inc. (KYTX) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Seeking Alpha Feed2026-09-14
Kyverna Therapeutics: Market Holding Flat Despite Progress To Approval
seekingalpha.com2026-08-13POS

For you

Charts, 10-year financials, peer comparison, screening and portfolio tracking for KYTX and 5,000+ tickers.

Create a free account — keep KYTX

For your agent

GET /api/data?ticker=KYTX

This page as JSON via rel="alternate" · REST API docs · MCP server (60 tools) · llms.txt